EDUARDO ADONIAS DE SOUSA
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neuromuscular Medicine
- Where
- MOORE, OK
- NPI
- 1992819700
- Received
- $406,193 in 538 records, 2019 to 2025 ($392,993 general, $13,200 research)
- As principal investigator
- $49,450 of research payments to others in 22 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 116 | $95,390 |
| 2024 | General payment | 121 | $111,826 |
| 2023 | General payment | 80 | $89,580 |
| 2022 | General payment | 37 | $38,162 |
| 2021 | General payment | 21 | $9,986 |
| 2021 | Research payment | 1 | $13,200 |
| 2020 | General payment | 56 | $28,741 |
| 2019 | General payment | 106 | $19,304 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 124 | $307,068 |
| Consulting Fee | 19 | $32,214 |
| Travel and Lodging | 104 | $28,554 |
| Food and Beverage | 279 | $14,039 |
| Research payment | 1 | $13,200 |
| Honoraria | 7 | $11,080 |
| Education | 4 | $35 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Amgen Inc. | $38 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | Amgen Inc. | $3,575 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-18 | Amgen Inc. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | Amgen Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | ARGENX US, INC. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-12-10 | Amgen Inc. | $555 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-09 | Amgen Inc. | $158 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-08 | Amgen Inc. | $121 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-04 | ARGENX US, INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-12-03 | CSL Behring | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Hizentra Biological, Immunology | 2025 | |
| 2025-11-20 | UCB, Inc. | $1,680 | Consulting Fee | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-11-17 | ARGENX US, INC. | $100 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-11-11 | ARGENX US, INC. | $116 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-11-08 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-08 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-07 | Janssen Biotech, Inc. | $30 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-07 | Janssen Biotech, Inc. | $18 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-07 | Janssen Biotech, Inc. | $18 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-05 | CSL Behring | $4,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Hizentra Biological, Immunology | 2025 | |
| 2025-11-05 | CSL Behring | $34 | Travel and Lodging | Cash or cash equivalent | Hizentra Biological, Immunology | 2025 | |
| 2025-11-05 | CSL Behring | $30 | Travel and Lodging | Cash or cash equivalent | Hizentra Biological, Immunology | 2025 | |
| 2025-11-05 | CSL Behring | $19 | Food and Beverage | Cash or cash equivalent | Hizentra Biological, Immunology | 2025 | |
| 2025-11-05 | CSL Behring | $14 | Travel and Lodging | Cash or cash equivalent | Hizentra Biological, Immunology | 2025 | |
| 2025-11-05 | CSL Behring | $10 | Food and Beverage | Cash or cash equivalent | Hizentra Biological, Immunology | 2025 | |
| 2025-11-04 | Janssen Scientific Affairs, LLC | $45 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-03 | Janssen Biotech, Inc. | $1,214 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-03 | Janssen Biotech, Inc. | $562 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-03 | Janssen Biotech, Inc. | $135 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-03 | Janssen Biotech, Inc. | $122 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-28 | CSL Behring | $873 | Travel and Lodging | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-10-28 | CSL Behring | $391 | Travel and Lodging | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-10-28 | CSL Behring | $240 | Travel and Lodging | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-10-28 | CSL Behring | $76 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-10-24 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-10-24 | UCB, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-10-21 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-10-11 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-07 | Janssen Biotech, Inc. | $1,125 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-07 | Janssen Biotech, Inc. | $123 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-06 | Takeda Pharmaceuticals U.S.A., Inc. | $48 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-30 | UCB, Inc. | $125 | Food and Beverage | In-kind items and services | Rystiggo Drug, Neurology | 2025 | |
| 2025-09-29 | UCB, Inc. | $819 | Travel and Lodging | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-09-29 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-29 | UCB, Inc. | $18 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-09-25 | ARGENX US, INC. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-09-17 | Amgen Inc. | $144 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-15 | UCB, Inc. | $15 | Travel and Lodging | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-09-09 | Janssen Biotech, Inc. | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-04 | ARGENX US, INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-09-02 | Amgen Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-28 | UCB, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-28 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2025 | |
| 2025-08-26 | UCB, Inc. | $71 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-26 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-19 | ARGENX US, INC. | $147 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-08-14 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-14 | UCB, Inc. | $117 | Travel and Lodging | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-12 | UCB, Inc. | $117 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-08-04 | ARGENX US, INC. | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-08-04 | ARGENX US, INC. | $85 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-29 | UCB, Inc. | $56 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-07-22 | ARGENX US, INC. | $124 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-07-14 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-07-12 | Janssen Biotech, Inc. | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-12 | Janssen Biotech, Inc. | $30 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-07-11 | ARGENX US, INC. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-11 | UCB, Inc. | $45 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | ARGENX US, INC. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-07-10 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2025 | |
| 2025-06-28 | Janssen Biotech, Inc. | $92 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-28 | Janssen Biotech, Inc. | $41 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-28 | Janssen Biotech, Inc. | $39 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-28 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $536 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $228 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $226 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-27 | Janssen Biotech, Inc. | $127 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-27 | Abbott Laboratories | $71 | Food and Beverage | In-kind items and services | INFINITY Device, Structural Heart | 2025 | |
| 2025-06-27 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-26 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-06-24 | ARGENX US, INC. | $122 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-06-24 | GE HEALTHCARE | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-23 | AstraZeneca Pharmaceuticals LP | $115 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-06-11 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-06-06 | ARGENX US, INC. | $1,562 | Consulting Fee | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-05-30 | ARGENX US, INC. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-05-30 | ARGENX US, INC. | $625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-14 | CSL Behring | $11 | Education | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-04-25 | ARGENX US, INC. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-24 | CSL Behring | $11 | Education | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-03-27 | Alexion Pharmaceuticals, Inc. | $175 | Consulting Fee | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-03-25 | Eisai Inc. | $27 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-03-14 | UCB, Inc. | $29 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2025 | |
| 2025-02-27 | Alexion Pharmaceuticals, Inc. | $5,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-25 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-02-25 | Biogen, Inc. | $20 | Food and Beverage | In-kind items and services | SKYCLARYS Drug, Neurology | 2025 | |
| 2025-02-08 | Alexion Pharmaceuticals, Inc. | $223 | Travel and Lodging | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-08 | Alexion Pharmaceuticals, Inc. | $66 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-08 | Alexion Pharmaceuticals, Inc. | $63 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-08 | Alexion Pharmaceuticals, Inc. | $30 | Food and Beverage | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-08 | Alexion Pharmaceuticals, Inc. | $30 | Travel and Lodging | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-08 | Alexion Pharmaceuticals, Inc. | $12 | Food and Beverage | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-07 | Alexion Pharmaceuticals, Inc. | $232 | Travel and Lodging | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-07 | Alexion Pharmaceuticals, Inc. | $208 | Travel and Lodging | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-07 | Alexion Pharmaceuticals, Inc. | $124 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-02-06 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-02-04 | AstraZeneca Pharmaceuticals LP | $97 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-02-04 | Alexion Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-01-15 | Impel Pharmaceuticals LLC | $17 | Food and Beverage | Cash or cash equivalent | TRUDHESA Drug, Antimigraine Agents | 2025 | |
| 2025-01-09 | ARGENX US, INC. | $1,562 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2025 | |
| 2025-01-09 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2025 | |
| 2025-01-09 | Teva Pharmaceuticals USA, Inc. | $25 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2025 | |
| 2024-12-10 | PFIZER INC. | $34 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2024 | |
| 2024-12-05 | UCB, Inc. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Biological, Neurology | 2024 | |
| 2024-12-02 | ARGENX US, INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2024 | |
| 2024-12-02 | ARGENX US, INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-12-02 | Alnylam Pharmaceuticals Inc. | $1,803 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-12-02 | Alnylam Pharmaceuticals Inc. | $176 | Travel and Lodging | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-11-21 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-11-21 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-11-13 | ARGENX US, INC. | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-11-13 | ARGENX US, INC. | $107 | Travel and Lodging | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-11-12 | UCB, Inc. | $1,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2024 | |
| 2024-11-12 | Alnylam Pharmaceuticals Inc. | $31 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-11-11 | Abbott Laboratories | $143 | Food and Beverage | In-kind items and services | INFINITY Device, Neuromodulation | 2024 | |
| 2024-11-11 | ARGENX US, INC. | $122 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-11-08 | ARGENX US, INC. | $122 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-11-05 | Alexion Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-10-31 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-10-29 | Amgen Inc. | $282 | Travel and Lodging | Cash or cash equivalent | UPLIZNA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-10-29 | AstraZeneca Pharmaceuticals LP | $117 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-10-29 | AstraZeneca Pharmaceuticals LP | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-10-22 | Amgen Inc. | $4,125 | Consulting Fee | Cash or cash equivalent | UPLIZNA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-10-18 | ARGENX US, INC. | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-10-18 | ARGENX US, INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-10-18 | ARGENX US, INC. | $172 | Travel and Lodging | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-10-18 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2024 | |
| 2024-10-10 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-10-09 | AstraZeneca Pharmaceuticals LP | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-10-08 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-10-08 | UCB, Inc. | $125 | Travel and Lodging | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-10-08 | ARGENX US, INC. | $34 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-10-05 | Amgen Inc. | $149 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-10-04 | Amgen Inc. | $150 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-10-03 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-10-02 | UCB, Inc. | $1,260 | Consulting Fee | Cash or cash equivalent | Zilbrysq Biological, Neurology | 2024 | |
| 2024-09-30 | AstraZeneca Pharmaceuticals LP | $97 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-09-26 | CSL Behring | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Hizentra Biological, Immunology | 2024 | |
| 2024-09-24 | ARGENX US, INC. | $9,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2024 | |
| 2024-09-24 | UCB, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-09-24 | ARGENX US, INC. | $35 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-09-24 | ARGENX US, INC. | $30 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2024 | |
| 2024-09-23 | UCB, Inc. | $56 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2024 | |
| 2024-09-17 | ARGENX US, INC. | $124 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-09-16 | ARGENX US, INC. | $119 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2024 | |
| 2024-09-10 | UCB, Inc. | $150 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-08-28 | Alnylam Pharmaceuticals Inc. | $2,318 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-08-27 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-08-16 | ARGENX US, INC. | $1,562 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYVGART Drug, Immunology | 2024 | |
| 2024-08-08 | UCB, Inc. | $420 | Consulting Fee | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-08-08 | UCB, Inc. | $420 | Consulting Fee | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-08-08 | UCB, Inc. | $210 | Consulting Fee | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-08-08 | UCB, Inc. | $210 | Consulting Fee | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-08-06 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-08-06 | UCB, Inc. | $101 | Travel and Lodging | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-08-03 | ARGENX US, INC. | $75 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-08-03 | ARGENX US, INC. | $58 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-08-03 | ARGENX US, INC. | $50 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-08-03 | ARGENX US, INC. | $8 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-08-03 | ARGENX US, INC. | $7 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-08-02 | ARGENX US, INC. | $125 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-07-30 | Alnylam Pharmaceuticals Inc. | $122 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-07-25 | CSL Behring | $4,192 | Consulting Fee | Cash or cash equivalent | Hizentra Biological, Immunology | 2024 | |
| 2024-07-25 | CSL Behring | $257 | Travel and Lodging | Cash or cash equivalent | Hizentra Biological, Immunology | 2024 | |
| 2024-07-13 | CSL Behring | $78 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2024 | |
| 2024-07-13 | CSL Behring | $65 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2024 | |
| 2024-07-13 | CSL Behring | $45 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2024 | |
| 2024-07-12 | ARGENX US, INC. | $426 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2024 | |
| 2024-07-12 | CSL Behring | $303 | Travel and Lodging | In-kind items and services | Hizentra Biological, Immunology | 2024 | |
| 2024-07-12 | ARGENX US, INC. | $204 | Travel and Lodging | Cash or cash equivalent | VYVGART Drug, Immunology | 2024 | |
| 2024-07-12 | CSL Behring | $124 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2024 | |
| 2024-06-18 | UCB, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-05-29 | UCB, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zilbrysq Drug, Neurology | 2024 | |
| 2024-05-20 | Alexion Pharmaceuticals, Inc. | $117 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-04-30 | UCB, Inc. | $113 | Food and Beverage | In-kind items and services | Zilbrysq Drug, Neurology | 2024 | |
| 2024-04-15 | Alnylam Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-04-09 | UCB, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rystiggo Drug, Neurology | 2024 | |
| 2024-04-09 | UCB, Inc. | $163 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2024 | |
| 2024-04-09 | Alexion Pharmaceuticals, Inc. | $44 | Travel and Lodging | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-04-09 | Alexion Pharmaceuticals, Inc. | $26 | Travel and Lodging | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-04-09 | Alexion Pharmaceuticals, Inc. | $15 | Travel and Lodging | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-04-09 | UCB, Inc. | $9 | Travel and Lodging | Cash or cash equivalent | Rystiggo Drug, Neurology | 2024 | |
| 2024-04-08 | Alexion Pharmaceuticals, Inc. | $4,720 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-04-08 | Alexion Pharmaceuticals, Inc. | $738 | Travel and Lodging | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-04-08 | Alexion Pharmaceuticals, Inc. | $317 | Travel and Lodging | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-04-08 | Alexion Pharmaceuticals, Inc. | $121 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 |
The latest 200 records of 538.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2024-07-10 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $4,000 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-07-01 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $70 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-07-01 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $70 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-05-01 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $70 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-04-01 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $70 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-03-26 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $50 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-03-21 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $200 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-03-12 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $19,999 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-03-01 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $70 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-02-01 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $70 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-01-01 | ARGENX US, INC. | MERCY MEDICAL RESEARCH INSTITUTE | $70 | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2023-12-01 | ARGENX US, INC. | MERCY RESEARCH | $70 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless St | 2023 |
| 2023-11-01 | ARGENX US, INC. | MERCY RESEARCH | $70 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless St | 2023 |
| 2023-08-01 | ARGENX US, INC. | MERCY RESEARCH | $548 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless St | 2023 |
| 2023-08-01 | ARGENX US, INC. | MERCY RESEARCH | $225 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless St | 2023 |
| 2023-07-19 | Genentech, Inc. | MERCY RESEARCH | $16,000 | Efficacy safety PK PD of satralizumab in patients with generalized Myasthenia Gravis | 2023 |
| 2023-05-01 | ARGENX US, INC. | MERCY RESEARCH | $104 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless St | 2023 |
| 2023-05-01 | ARGENX US, INC. | MERCY RESEARCH | $232 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless St | 2023 |
| 2023-05-01 | ARGENX US, INC. | MERCY RESEARCH | $42 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless St | 2023 |
| 2023-03-13 | Eli Lilly and Company | ST JOHNS MEDICAL RESEARCH INSTITUTE INC | $2,300 | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2023 |
| 2022-12-08 | Eli Lilly and Company | ST JOHNS MEDICAL RESEARCH INSTITUTE INC | $3,295 | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2022 |
| 2021-12-01 | Eli Lilly and Company | ST JOHNS MEDICAL RESEARCH INSTITUTE INC | $1,825 | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Moore, OK, county Cleveland County, OK, state Oklahoma; placed by its city name.
| Measure | Place (city or town) Moore, OK | County Cleveland County, OK | State Oklahoma |
|---|---|---|---|
| Population B01003 | 63,420 | 300,047 | 4,028,634 |
| Population, 2020 census P1 | 62,793 | 295,528 | 3,959,353 |
| Median age B01002 | 34.1 | 35.4 | 37.0 |
| Under 18 B01001 | 25.7% | 20.4% | 24.0% |
| 65 and over B01001 | 13.3% | 14.9% | 16.3% |
| Households B11001 | 23,671 | 116,799 | 1,562,389 |
| Foreign born B05002 | 5.2% | 6.6% | 6.4% |
| Median household income B19013 | $80,420 | $77,068 | $65,039 |
| Median family income B19113 | $95,076 | $98,966 | $82,385 |
| Per capita income B19301 | $37,779 | $39,391 | $35,624 |
| Poverty rate B17001 | 11.4% | 12.9% | 15.3% |
| Unemployment rate B23025 | 4.7% | 4.8% | 5.0% |
| Civilian labor force B23025 | 32,927 | 157,031 | 1,921,413 |
| Mean commute (minutes) B08013 | 22.9 | 23.7 | 22.4 |
| Bachelor's degree or higher B15003 | 29.1% | 36.2% | 28.3% |
| Housing units B25001 | 24,995 | 124,442 | 1,775,127 |
| Owner-occupied B25003 | 67.9% | 63.9% | 65.8% |
| Renters B25003 | 32.1% | 36.1% | 34.2% |
| Median home value B25077 | $204,500 | $235,700 | $199,800 |
| Median gross rent B25064 | $1,340 | $1,167 | $1,014 |
| White, not Hispanic B03002 | 66.4% | 67.2% | 62.1% |
| Black B03002 | 5.5% | 4.6% | 6.8% |
| Hispanic or Latino B03002 | 13.1% | 11.0% | 12.7% |
| Asian B03002 | 3.2% | 4.7% | 2.4% |
| American Indian and Alaska Native B03002 | 2.7% | 3.4% | 6.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Moore, OK.
Comments